Fig. 3
FNDC3B promoted OS progression in vitro and in vivo. CCK8 assays (A, B), EdU assays (C, D), wound-healing assays (E, F) and transwell assays (G, H) assessing the effects of FNDC3B overexpression and knockdown on OS cells proliferation, migration and invasion. I Xenograft assays assessing the effects of FNDC3B knockdown on OS tumor growth in vivo; scale bar represents 1 cm. Data were shown as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001